Human Cytomegalovirus Fcγ Binding Proteins gp34 and gp68 Antagonize Fcγ Receptors I, II and III

English version České info

Herpes viruses persist lifelong continuously alternating between latency and virus production and transmission. The latter events occur despite the presence of immune IgG antibodies. IgG acts by neutralization of virions and activation of immune cells bearing one or more surface receptors, called FcγRs, recognizing the constant Fc domain of IgG. Activating FcγRs induce a wide range of immune responses, including antibody dependent cellular cytotoxicity (ADCC) of virus-infected cells by natural killer (NK) cells, cytokine secretion and the uptake of immune complexes to enhance antigen presentation to T cells. We demonstrate that the HCMV glycoproteins RL11/gp34 and UL119-118/gp68 block IgG-mediated activation of FcγRs. A novel reporter cell-based assay was used to test FcγRs individually and assess their relative susceptibility to each antagonist. This approach revealed that gp34 and gp68 block triggering of activating FcγRs, i.e. FcγRI (CD64), FcγRII (CD32A) and FcγRIII (CD16). Co-immunoprecipitation showed the formation of ternary complexes containing IgG, IgG-bound antigen and the viral antagonists on the cell surface. Assigning the redundant abilities of HCMV to hinder IgG effector responses to the viral Fc binding proteins, we discuss gp34 and gp68 as potential culprits which might contribute to the limited efficacy of therapeutic IgG against HCMV.

Vyšlo v časopise: Human Cytomegalovirus Fcγ Binding Proteins gp34 and gp68 Antagonize Fcγ Receptors I, II and III. PLoS Pathog 10(5): e32767. doi:10.1371/journal.ppat.1004131
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1004131

Souhrn

Zdroje

1. Mocarski,E.S., Shenk,T., and Pass RF (2007) Cytomegaloviruses. In: Knipe, D.K and Howley PM, editor. Field's Virology. Philadephia: Lippincott, Williams & Wilkins. pp. 2701–2772.

2. Stern-GinossarN, WeisburdB, MichalskiA, LeVTK, HeinMY, et al. (2012) Decoding human cytomegalovirus. Science 338: 1088–1093.

3. Quinnan GV, MasurH, RookAH, ArmstrongG, FrederickWR, et al. (1984) Herpesvirus infections in the acquired immune deficiency syndrome. JAMA 252: 72–77.

4. PolićB, HengelH, KrmpotićA, TrgovcichJ, PavićI, et al. (1998) Hierarchical and redundant lymphocyte subset control precludes cytomegalovirus replication during latent infection. J Exp Med 188: 1047–1054.

5. Miller-KittrellM, SparerTE (2009) Feeling manipulated: cytomegalovirus immune manipulation. Virol J 6: 4.

6. MocarskiES (2002) Immunomodulation by cytomegaloviruses: manipulative strategies beyond evasion. Trends Microbiol 10: 332–339.

7. MocarskiES (2004) Immune escape and exploitation strategies of cytomegaloviruses: impact on and imitation of the major histocompatibility system. Cell Microbiol 6: 707–717.

8. JonjićS, PavićI, PolićB, CrnkovićI, LucinP, et al. (1994) Antibodies are not essential for the resolution of primary cytomegalovirus infection but limit dissemination of recurrent virus. J Exp Med 179: 1713–1717.

9. KlenovsekK, WeiselF, SchneiderA, AppeltU, JonjicS, et al. (2007) Protection from CMV infection in immunodeficient hosts by adoptive transfer of memory B cells. Blood 110: 3472–3479.

10. CekinovićD, GolemacM, PugelEP, TomacJ, Cicin-SainL, et al. (2008) Passive immunization reduces murine cytomegalovirus-induced brain pathology in newborn mice. J Virol 82: 12172–12180.

11. NigroG, AdlerSP, La TorreR, BestAM (2005) Passive immunization during pregnancy for congenital cytomegalovirus infection. N Engl J Med 353: 1350–1362.

12. RaananiP, Gafter-GviliA, PaulM, Ben-BassatI, LeiboviciL, et al. (2009) Immunoglobulin prophylaxis in hematopoietic stem cell transplantation: systematic review and meta-analysis. J Clin Oncol 27: 770–781.

13. HodsonEM, JonesCA, StrippoliGFM, WebsterAC, CraigJC (2007) Immunoglobulins, vaccines or interferon for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane database Syst Rev CD005129.

14. BoeckhM, BowdenRA, StorerB, ChaoNJ, SpielbergerR, et al. (2001) Randomized, placebo-controlled, double-blind study of a cytomegalovirus-specific monoclonal antibody (MSL-109) for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 7: 343–351.

15. BruhnsP, IannascoliB, EnglandP, MancardiDA, FernandezN, et al. (2009) Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood 113: 3716–3725.

16. NimmerjahnF, RavetchJV (2007) Fc-receptors as regulators of immunity. Adv Immunol 96: 179–204.

17. BruhnsP (2012) Properties of mouse and human IgG receptors and their contribution to disease models. Blood 119: 5640–5649.

18. ErnstLK, MetesD, HerbermanRB, MorelPA (2002) Allelic polymorphisms in the FcgammaRIIC gene can influence its function on normal human natural killer cells. J Mol Med (Berl) 80: 248–257.

19. MetesD, ManciuleaM, PretruscaD, RabinowichH, ErnstLK, et al. (1999) Ligand binding specificities and signal transduction pathways of Fc gamma receptor IIc isoforms: the CD32 isoforms expressed by human NK cells. Eur J Immunol 29: 2842–2852.

20. FurukawaT, HornbergerE, SakumaS, PlotkinSA (1975) Demonstration of immunoglobulin G receptors induced by human cytomegalovirus. J Clin Microbiol 2: 332–336.

21. BudtM, ReinhardH, BiglA, HengelH (2004) Herpesviral Fcgamma receptors: culprits attenuating antiviral IgG? Int Immunopharmacol 4: 1135–1148.

22. AtalayR, ZimmermannA, WagnerM, BorstE, BenzC, et al. (2002) Identification and expression of human cytomegalovirus transcription units coding for two distinct Fcgamma receptor homologs. J Virol 76: 8596–8608.

23. LilleyBN, PloeghHL, TirabassiRS (2001) Human cytomegalovirus open reading frame TRL11/IRL11 encodes an immunoglobulin G Fc-binding protein. J Virol 75: 11218–11221.

24. SpragueER, ReinhardH, CheungEJ, FarleyAH, TrujilloRD, et al. (2008) The human cytomegalovirus Fc receptor gp68 binds the Fc CH2-CH3 interface of immunoglobulin G. J Virol 82: 3490–3499.

25. KutzaAS, MuhlE, HacksteinH, KirchnerH, BeinG (1998) High incidence of active cytomegalovirus infection among septic patients. Clin Infect Dis 26: 1076–1082.

26. RossSA, AroraN, NovakZ, FowlerKB, BrittWJ, et al. (2010) Cytomegalovirus reinfections in healthy seroimmune women. J Infect Dis 201: 386–389.

27. HansenSG, PowersCJ, RichardsR, VenturaAB, FordJC, et al. (2010) Evasion of CD8+ T cells is critical for superinfection by cytomegalovirus. Science 328: 102–106.

28. Corrales-AguilarE, TrillingM, ReinhardH, Mercé-MaldonadoE, WideraM, et al. (2013) A novel assay for detecting virus-specific antibodies triggering activation of Fcγ receptors. J Immunol Methods 387: 21–35.

29. JohnsonDC, FrameMC, LigasMW, CrossAM, StowND (1988) Herpes simplex virus immunoglobulin G Fc receptor activity depends on a complex of two viral glycoproteins, gE and gI. J Virol 62: 1347–1354.

30. DubinG, SocolofE, FrankI, FriedmanHM (1991) Herpes simplex virus type 1 Fc receptor protects infected cells from antibody-dependent cellular cytotoxicity. J Virol 65: 7046–7050.

31. HaleniusA, HaukaS, DölkenL, StindtJ, ReinhardH, et al. (2011) Human cytomegalovirus disrupts the major histocompatibility complex class I peptide-loading complex and inhibits tapasin gene transcription. J Virol 85: 3473–3485.

32. HoetzeneckerK, HackerS, HoetzeneckerW, SadeghiK, SachetM, et al. (2007) Cytomegalovirus hyperimmunoglobulin: mechanisms in allo-immune response in vitro. Eur J Clin Invest 37: 978–986.

33. LeVTK, TrillingM, HengelH (2011) The cytomegaloviral protein pUL138 acts as potentiator of tumor necrosis factor (TNF) receptor 1 surface density to enhance ULb'-encoded modulation of TNF-α signaling. J Virol 85: 13260–13270.

34. SinzgerC, HahnG, DigelM, KatonaR, SampaioKL, et al. (2008) Cloning and sequencing of a highly productive, endotheliotropic virus strain derived from human cytomegalovirus TB40/E. J Gen Virol 89: 359–368.

35. MorizonoK, KuA, XieY, HaruiA, KungSKP, et al. (2010) Redirecting lentiviral vectors pseudotyped with Sindbis virus-derived envelope proteins to DC-SIGN by modification of N-linked glycans of envelope proteins. J Virol 84: 6923–6934.

36. LindeGA, HammarströmL, PerssonMA, SmithCI, SundqvistVA, et al. (1983) Virus-specific antibody activity of different subclasses of immunoglobulins G and A in cytomegalovirus infections. Infect Immun 42: 237–244.

37. GuptaCK, LeszczynskiJ, GuptaRK, SiberGR (1996) IgG subclass antibodies to human cytomegalovirus (CMV) in normal human plasma samples and immune globulins and their neutralizing activities. Biologicals 24: 117–124.

38. WigerD, MichaelsenTE (1985) Binding site and subclass specificity of the herpes simplex virus type 1-induced Fc receptor. Immunology 54: 565–572.

39. JohanssonPJ, HallbergT, OxeliusVA, GrubbA, BlombergJ (1984) Human immunoglobulin class and subclass specificity of Fc receptors induced by herpes simplex virus type 1. J Virol 50: 796–804.

40. MandelboimO, MalikP, DavisDM, JoCH, BoysonJE, et al. (1999) Human CD16 as a lysis receptor mediating direct natural killer cell cytotoxicity. Proc Natl Acad Sci U S A 96: 5640–5644.

41. CooperMA, FehnigerTA, CaligiuriMA (2001) The biology of human natural killer-cell subsets. Trends Immunol 22: 633–640.

42. CouziL, PitardV, SicardX, GarrigueI, HawcharO, et al. (2012) Antibody-dependent anti-cytomegalovirus activity of human γδ T cells expressing CD16 (FcγRIIIa). Blood 119: 1418–1427.

43. AlterG, MalenfantJM, AltfeldM (2004) CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods 294: 15–22.

44. GumáM, AnguloA, López-BotetM (2006) NK cell receptors involved in the response to human cytomegalovirus infection. Curr Top Microbiol Immunol 298: 207–223.

45. WilkinsonGWG, TomasecP, StantonRJ, ArmstrongM, Prod'hommeV, et al. (2008) Modulation of natural killer cells by human cytomegalovirus. J Clin Virol 41: 206–212.

46. LenacT, BudtM, ArapovicJ, HasanM, ZimmermannA, et al. (2006) The herpesviral Fc receptor fcr-1 down-regulates the NKG2D ligands MULT-1 and H60. J Exp Med 203: 1843–1850.

47. FrankI, FriedmanHM (1989) A novel function of the herpes simplex virus type 1 Fc receptor: participation in bipolar bridging of antiviral immunoglobulin G. J Virol 63: 4479–4488.

48. Van VlietKE, De Graaf-MiltenburgLA, VerhoefJ, Van StrijpJA (1992) Direct evidence for antibody bipolar bridging on herpes simplex virus-infected cells. Immunology 77: 109–115.

49. SpragueER, WangC, BakerD, BjorkmanPJ (2006) Crystal structure of the HSV-1 Fc receptor bound to Fc reveals a mechanism for antibody bipolar bridging. PLoS Biol 4: e148.

50. SpragueER, MartinWL, BjorkmanPJ (2004) pH dependence and stoichiometry of binding to the Fc region of IgG by the herpes simplex virus Fc receptor gE-gI. J Biol Chem 279: 14184–14193.

51. SchoppelK, KropffB, SchmidtC, VornhagenR, MachM (1997) The humoral immune response against human cytomegalovirus is characterized by a delayed synthesis of glycoprotein-specific antibodies. J Infect Dis 175: 533–544.

52. LubinskiJ, NagashunmugamT, FriedmanHM (1998) Viral interference with antibody and complement. Semin Cell Dev Biol 9: 329–337.

53. NagashunmugamT, LubinskiJ, WangL, GoldsteinLT, WeeksBS, et al. (1998) In vivo immune evasion mediated by the herpes simplex virus type 1 immunoglobulin G Fc receptor. J Virol 72: 5351–5359.

54. LubinskiJM, LazearHM, AwasthiS, WangF, FriedmanHM (2011) The herpes simplex virus 1 IgG fc receptor blocks antibody-mediated complement activation and antibody-dependent cellular cytotoxicity in vivo. J Virol 85: 3239–3249.

55. SondermannP, HuberR, OosthuizenV, JacobU (2000) The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc gammaRIII complex. Nature 406: 267–273.

56. RadaevS, MotykaS, FridmanWH, Sautes-FridmanC, SunPD (2001) The structure of a human type III Fcgamma receptor in complex with Fc. J Biol Chem 276: 16469–16477.

57. SondermannP, OosthuizenV (2002) X-ray crystallographic studies of IgG-Fc gamma receptor interactions. Biochem Soc Trans 30: 481–486.

58. RouxKH, StreletsL, MichaelsenTE (1997) Flexibility of human IgG subclasses. J Immunol 159: 3372–3382.

59. HengelH, BruneW, KoszinowskiUH (1998) Immune evasion by cytomegalovirus–survival strategies of a highly adapted opportunist. Trends Microbiol 6: 190–197.

60. PowersC, FrühK (2008) Rhesus CMV: an emerging animal model for human CMV. Med Microbiol Immunol 197: 109–115.

61. JonjićS, BabićM, PolićB, KrmpotićA (2008) Immune evasion of natural killer cells by viruses. Curr Opin Immunol 20: 30–38.

62. HengelH, KoszinowskiUH (1997) Interference with antigen processing by viruses. Curr Opin Immunol 9: 470–476.

63. ArapovicJ, LenacT, AntulovR, PolicB, RuzsicsZ, et al. (2009) Differential susceptibility of RAE-1 isoforms to mouse cytomegalovirus. J Virol 83: 8198–8207.

64. MinternJD, KlemmEJ, WagnerM, PaquetME, NapierMD, et al. (2006) Viral interference with B7-1 costimulation: a new role for murine cytomegalovirus fc receptor-1. J Immunol 177: 8422–8431.

65. CorteseM, CalòS, D'AurizioR, LiljaA, PacchianiN, et al. (2012) Recombinant human cytomegalovirus (HCMV) RL13 binds human immunoglobulin G Fc. PLoS One 7: e50166.

66. KhanN (n.d.) The immunological burden of human cytomegalovirus infection. Arch Immunol Ther Exp (Warsz) 55: 299–308.

67. RadsakK, EickmannM, MockenhauptT, BognerE, KernH, et al. (1996) Retrieval of human cytomegalovirus glycoprotein B from the infected cell surface for virus envelopment. Arch Virol 141: 557–572.

68. ManleyK, AndersonJ, YangF, SzustakowskiJ, OakeleyEJ, et al. (2011) Human cytomegalovirus escapes a naturally occurring neutralizing antibody by incorporating it into assembling virions. Cell Host Microbe 10: 197–209.

69. MacagnoA, BernasconiNL, VanzettaF, DanderE, SarasiniA, et al. (2010) Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complex. J Virol 84: 1005–1013.

70. PlachterB, SinzgerC, JahnG (1996) Cell types involved in replication and distribution of human cytomegalovirus. Adv Virus Res 46: 195–261.

71. BorstEM, HahnG, KoszinowskiUH, MesserleM (1999) Cloning of the human cytomegalovirus (HCMV) genome as an infectious bacterial artificial chromosome in Escherichia coli: a new approach for construction of HCMV mutants. J Virol 73: 8320–8329.

72. DingwellKS, BrunettiCR, HendricksRL, TangQ, TangM, et al. (1994) Herpes simplex virus glycoproteins E and I facilitate cell-to-cell spread in vivo and across junctions of cultured cells. J Virol 68: 834–845.

73. BellS, CranageM, BorysiewiczL, MinsonT (1990) Induction of immunoglobulin G Fc receptors by recombinant vaccinia viruses expressing glycoproteins E and I of herpes simplex virus type 1. J Virol 64: 2181–2186.

74. KrmpoticA, HasanM, LoewendorfA, SauligT, HaleniusA, et al. (2005) NK cell activation through the NKG2D ligand MULT-1 is selectively prevented by the glycoprotein encoded by mouse cytomegalovirus gene m145. J Exp Med 201: 211–220.

75. WagnerM, GutermannA, PodlechJ, ReddehaseMJ, KoszinowskiUH (2002) Major histocompatibility complex class I allele-specific cooperative and competitive interactions between immune evasion proteins of cytomegalovirus. J Exp Med 196: 805–816.

76. MesserleM, CrnkovicI, HammerschmidtW, ZieglerH, KoszinowskiUH (1997) Cloning and mutagenesis of a herpesvirus genome as an infectious bacterial artificial chromosome. Proc Natl Acad Sci U S A 94: 14759–14763.

77. SnydmanDR, WernerBG, Heinze-LaceyB, BerardiVP, TilneyNL, et al. (1987) Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients. N Engl J Med 317: 1049–1054.